Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma-Reference-Cited by-同舟云学术

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma

Published:2023-01 Issue:1 Volume:23 Page:e41-e50
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Foureau David M.^ORCID,Paul Barry A.,Guo Fei,Lipford Edward H.,Fesenkova Kateryna,Tjaden Elise,Drummond Kendra^ORCID,Bhutani Manisha,Atrash Shebli^ORCID,Ndiaye Ami,Varga Cindy,Voorhees Peter M.,Usmani Saad Z.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference24 articles.

1. Clinical applications and future directions of minimal residual disease testing in multiple Myeloma;Oliva;Front Oncol,2020

2. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma;Munshi;Blood Adv,2020

3. Measurable residual disease in multiple myeloma: ready for clinical practice?;Burgos;J Hematol Oncol,2020

4. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis;Avet-Loiseau;Clin Lymphoma Myeloma Leuk,2020

5. Measurable residual disease by next-generation flow cytometry in multiple myeloma;Paiva;J Clin Oncol,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Status of Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasms in Korea;Annals of Laboratory Medicine;2023-12-26

2. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index;Blood Cancer Journal;2023-12-01

3. Flow Cytometry in Diagnosis, Prognostication, and Monitoring of Multiple Myeloma and Related Disorders;Clinics in Laboratory Medicine;2023-09

4. Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients;Targeted Oncology;2023-09

5. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse;Clinical Lymphoma Myeloma and Leukemia;2023-07